文献速递乳腺癌放疗

残留三阴性乳腺癌术后同步与序贯卡培他滨放化疗的多中心比较

Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-12-11

这项多中心回顾性研究分析了491例新辅助系统治疗后残留三阴性乳腺癌患者,比较术后同步放疗联合卡培他滨(RT+CAP,n=236)与序贯放疗后卡培他滨(RT→CAP,n=255)的疗效与安全性。中位随访41.8个月,RT+CAP组4年无病生存率74.6% vs 63.7%(P=.045)、总生存率86.8% vs 78.3%(P=.006)均优于RT→CAP组,且≥2级毒性和因毒性停用卡培他滨的发生率无差异。

要点

  • RT+CAP组4年DFS 74.6% vs RT→CAP组63.7%,P=.045
  • RT+CAP组4年OS 86.8% vs RT→CAP组78.3%,P=.006
  • 低疾病负荷患者(ypT0-1、ypN0或仅腋窝I级、或Ki67<15%)中RT+CAP的DFS和OS更优

核心结论

  • 与序贯放疗后卡培他滨相比,同步放疗联合卡培他滨在残留三阴性乳腺癌患者中改善肿瘤学结局且不增加不良事件,作者认为其是有前景的治疗选择。

研究设计与样本

  • 多中心回顾性研究,纳入14家三级医院491例新辅助系统治疗后残留三阴性乳腺癌患者,术后接受RT→CAP(n=255)或RT+CAP(n=236)。
  • 采用Kaplan-Meier法分析生存结局,多因素Cox回归校正潜在混杂因素。

主要发现

  • 两组基线特征无显著差异,中位随访41.8个月,总体4年无病生存率和总生存率分别为68.8%和82.4%。
  • RT+CAP组4年无病生存率74.6% vs RT→CAP组63.7%(P=.045)。
  • RT+CAP组4年总生存率86.8% vs RT→CAP组78.3%(P=.006)。
  • 在低疾病负荷患者(ypT0-1、ypN0或仅腋窝I级、或Ki67<15%)中,RT+CAP显示出更优的无病生存和总生存结局。
  • ≥2级毒性和因毒性停用卡培他滨的发生率两组无差异,提示RT+CAP耐受良好。

关键数值与推荐

  • RT+CAP组4年无病生存率74.6% vs RT→CAP组63.7%(P=.045)。
  • RT+CAP组4年总生存率86.8% vs RT→CAP组78.3%(P=.006)。
  • 低疾病负荷定义为ypT0-1、ypN0或仅腋窝I级、或Ki67<15%。

临床怎么用

  • 作者认为,对于新辅助系统治疗后残留的三阴性乳腺癌患者,同步放疗联合卡培他滨相比序贯方案改善肿瘤学结局且不增加不良事件,是有前景的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the aggressive nature and poor prognosis of triple-negative breast cancer (TNBC), adjuvant capecitabine has been the standard therapy for residual disease after preoperative systemic therapy (PST). However, the optimal sequence of postoperative radiation therapy (RT) and capecitabine remains unclear. This study evaluated the efficacy and safety of concurrent RT and capecitabine (RT+CAP) versus sequential RT followed by capecitabine (RT→CAP) in patients with residual TNBC after PST. METHODS AND MATERIALS: In this multicenter retrospective study, data from 491 patients treated at 14 tertiary hospitals were analyzed. The patients received either postoperative RT→CAP (n = 255) or RT+CAP (n = 236). Survival outcomes were analyzed using the Kaplan-Meier method, and multivariable Cox regression was used to adjust for potential confounders. RESULTS: There were no significant differences in the baseline characteristics between the 2 groups. With a median follow-up of 41.8 months, the 4-year rates of disease-free survival (DFS) and overall survival (OS) were 68.8% and 82.4%, respectively. The RT+CAP group demonstrated improvements in DFS (74.6% vs 63.7%, P = .045) and OS (86.8% vs 78.3%, P = .006) compared with the RT→CAP group. Specifically, RT+CAP showed superior DFS and OS outcomes in patients with a low disease burden (ypT0-1, ypN0/axillar level I only, or Ki67 <15%). Additionally, the incidence of ≥grade 2 toxicities and discontinuation of capecitabine because of toxicity did not differ, indicating that RT+CAP was well tolerated. CONCLUSIONS: RT+CAP offers improvements in oncologic outcomes without an increase in adverse events compared with RT→CAP, suggesting it is a promising treatment option for patients with residual TNBC after PST.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Kim N, Kim SS, Cho WK, et al. Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative Study. Int J Radiat Oncol Biol Phys. 2024. PMID: 39672514. doi:10.1016/j.ijrobp.2024.11.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。